A platform for rational Multimodal Therapies
Tangramed is an AI-enabled drug discovery and development company specialized in network pharmacology and rational Multimodal Therapies. We combine proprietary computational tools, multimodal therapy know-how and translational development expertise to support partner collaborations and internal asset creation.
Engineering Multimodal Therapies.
Tangramed Biotech is a company specialized in network pharmacology and rational Multimodal Therapies for complex diseases. We help pharma, biotech and investment teams navigate biological complexity to prioritize robust therapeutic hypotheses.
Network Pharmacology
We integrate multi-omics data and disease networks to identify high-potential targets and therapeutic combinations.
Integral Therapy Design
Our proprietary framework designs rational Multimodal Therapies that address heterogeneous disease biology.
Patient Avatar Cohort
We use patient-derived models to benchmark robustness and validate therapeutic concepts across biological diversity.
The Tangramed Advantage.
We bridge the gap between complex biology and actionable therapeutic decisions through a proprietary platform architecture.
Network-Level Reasoning
Our AI integrates multi-omics and disease networks to prioritize targets and combinations that single-target approaches often miss.
MMT Design Logic
We design rational Multimodal Therapies that converge multiple mechanisms into a coherent, testable concept with biological rationale.
Robustness Testing
Our Patient Avatar Cohort (PAC) testing benchmarks therapeutic concepts across biological diversity to support translational decision-making.
Experience from discovery to clinic.
Deep expertise in network pharmacology and multimodal therapy development, bridging the gap between complex biology and actionable clinical decisions.
Network Pharmacology & MMT Experience
19 years of team experience in network pharmacology and multimodal therapy development.
Partner-funded Collaborations
Signed AI-service collaborations in oncology and neurodegeneration, subject to approved partner wording.
Discovery to Clinic
Experience across discovery, preclinical research, clinical development, regulatory strategy, CMC and financing.
Human Expert Curation
AI-assisted outputs are interpreted by Tangramed scientists and development experts.
Multimodal Therapy Precedent
The team previously generated and advanced PXT3003, a clinically advanced Multimodal Therapy for Charcot-Marie-Tooth disease type 1A.
Translational Decision Focus
Projects deliver ranked outputs, biological rationale, limitations and recommended next steps.
Execution Model.
Tangramed combines internal scientific and development expertise with specialized experimental and translational partners to turn complex biological questions into actionable decisions.
Scientific Expertise
Our internal team brings 19 years of experience in network pharmacology and multimodal therapy development, ensuring biological rigor at every stage.
Translational Partners
We collaborate with specialized experimental partners to validate biological hypotheses and translate complex network-level concepts into preclinical evidence.
Decision Architecture
Our framework integrates AI-assisted prioritization with expert curation to deliver ranked outputs and biological rationale for high-stakes R&D decisions.
Managing Team.
Prof. Daniel Cohen
Co-founder, Head of Science
A mathematician and medical geneticist, Prof. Cohen is the author of the first human genome map, the inventor of GWAS technology, and a pioneer in the genetics of longevity.
Â
More than 150 peer-reviewed publications, more than 30 patents, and a continuous pioneer of technology (genomics, pharmacogenomics and network pharmacology).
Â
Founder of Millennium, Moleac, Pharnext, GeneNet.
Dr. Jinchao Yu
Co-founder, CSO
During his PhD in bioinformatics, Dr. Jinchao Yu won the international CAPRI competition for three consecutive years in the fields of structural bioinformatics and machine learning, and published 10 peer-reviewed publications.
Â
Then, he served as Chief AI Scientist at Pharnext and its joint venture GeneNet, where he helped build AI platforms to design multimodal therapies and contributed to positioning Pharnext as a leading AI-driven drug discovery company globally.
Dr. Rodolphe Hajj
COO
Rodolphe Hajj, PhD, MBA, is a life sciences executive with 20+ years across pharma, biotech, MedTech and startups. He helped advance multimodal drug-combination programs from discovery to clinical Phases I, II and III.
​
At Tangramed, he bridges science, development, partnerships and financing to turn Multimodal Therapy concepts into executable programs.